<DOC>
	<DOCNO>NCT01234519</DOCNO>
	<brief_summary>The purpose study determine appropriate dose AEZS-108 treat patient tumor urinary system .</brief_summary>
	<brief_title>A Phase I/II Trial AEZS-108 Urothelial Cancer Patients Who Failed Platinum-chemotherapy</brief_title>
	<detailed_description>AEZS-108 investigational drug , combine luteinizing hormone-releasing hormone ( LHRH ) , hormone doxorubicin ( drug approve treat different type cancer ) . Some tumor , find urinary system ( also call urothelial carcinoma ) , LHRH hormone receptor LHRH hormone part AEZS-108 attract . AEZS-108 expect work accumulate mostly surface cancer cell LHRH hormone receptor deliver doxorubicin directly cell kill . This would allow use doxorubicin lower dos thus would cause less toxicity . In first part study , appropriate dose AEZS-108 determine base side effect . The best dose high one without severe side effect . In second part study , best dose AEZS-108 give determine efficacy stop tumor progressing .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<criteria>Histologically cytologically confirm locally advanced metastatic urothelial carcinoma Expression LHRH receptor confirm immunohistochemistry archival cancer tissue Measurable disease radiological study Patients Locally advanced unresectable metastatic urothelial carcinoma Documented progression least one prior chemotherapy regimen must incorporate platinum base therapy Left ventricular ejection fraction ( EF ) &gt; 50 % Eastern cooperative oncology group ( ECOG ) status 0 , 1 2 Adequate bone marrow , renal hepatic function Prior treatment allergy component AEZS108 Active second malignancy nonmelanoma skin cancer Ongoing use LHRH agonist ( antagonist ) Presence active infection fever &gt; 38.5 C , parenchymal brain metastasis uncontrolled intercurrent illness Prior exposure anthracyclines anthracenediones include doxorubicin , daunorubicin , mitoxantrone Patients receive radiotherapy within 4 week entry Major surgery within last 4 week minor surgery last 7 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>ureter cancer</keyword>
	<keyword>renal pelvis cancer</keyword>
	<keyword>bladder cancer</keyword>
	<keyword>urethra</keyword>
</DOC>